US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.15 against a street estimate of 0.97 — a beat of 18.6%.
Analysts rate Indivior PLC Ordinary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $49.00.
CONFIDENT Supernus and Indivior merge in all-stock deal creating $2.2B CNS leader. 11 marketed products, 5 growth drivers, $125M annual cost synergies, 41% EBITDA margin. Closing Q4 2026. Q2 2026 Call focused on merged entity; no geographic breakdown provided. Analysts pressed on BD capacity (firepower/indications), SUBLOCADE competitive durability (IP/manufacturing barriers), and additional synergy upside. Management emphasized historical M&A discipline, complex LAI manufacturing moat, and deferred specificity on additional savings until post-close. Downplayed emerging competitive threats (orexin, GLP-1) as early-stage. 2026-08-03…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.83% |
| Vanguard Portfolio Management, LLC | 6.31% |
| Oaktree Capital Management LLC | 5.59% |
| Vanguard Capital Management, LLC | 4.47% |
| State Street Corp | 3.92% |
| Two Seas Capital LP | 3.80% |
| Fuller & Thaler Asset Management Inc | 3.62% |
| Madison Avenue Partners, LP | 3.45% |
| Document | Date |
|---|---|
| Current report · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Indivior manufactures and supplies SUBOXONE® Tablets and SUBUTEX® | 2026-09-15 |
| Quarterly report · Q2 2026 INDIVIOR PHARMACEUTICALS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net revenue Q2 2026: $343 million (vs. $302 million Q2 2025; +13.6% increas | 2026-08-03 |
| Reg FD disclosure · Q3 2026 INDIVIOR PHARMACEUTICALS 8-K SUMMARY HEADLINE NUMBERS • Filing Date: August 3, 2026 • Company: Indivior Pharmaceuticals, Inc. (Ticker: INDV, Nasdaq) | 2026-08-03 |
| Results announced · Q3 2026 INDIVIOR PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total net revenue Q2 2026: $343 million, up 14% year-over-year (vs. $302 millio | 2026-08-03 |
| Material agreement · Q3 2026 INDIVIOR PHARMACEUTICALS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Agreement signed August 1, 2026 between Indivior Pharmaceuticals, Inc. a | 2026-08-03 |
| Board / officer change · Q2 2026 INDIVIOR PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 13, 2026 with 100,407,722 shares present or | 2026-05-15 |
| Quarterly report · Q1 2026 INDIVIOR PHARMACEUTICALS, INC. - FORM 10-Q SUMMARY For Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Net revenue: $317 million (Q1 2026) vs. | 2026-04-30 |
| Proxy statement · Q2 2026 INDIVIOR PHARMACEUTICALS, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect eight director nominees for one-ye | 2026-03-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entered into merger agreement with Supernus Pharmaceuticals Indivior Pharmaceuticals announced on August 1, 2026 that it has agreed to merge with Supernus Pharmaceuticals in an all-stock transaction. Under the merger agreement, each Supernus share wi | 2026-08-03 |
| Agreement and Plan of Merger executed with Supernus Pharmaceuticals Indivior Pharmaceuticals announced on August 3, 2026, that it has signed a merger agreement to acquire Supernus Pharmaceuticals. The companies executed the Agreement and Plan of Merger dated | 2026-08-03 |
| Accelerated share repurchase agreement for $175 million announced Indivior Pharmaceuticals announced on May 4, 2026, that it entered into an accelerated share repurchase (ASR) agreement with an investment bank to buy back $175 million of its own stock. Thi | 2026-05-04 |
| Financial guidance for 2026 announced with updated corporate presentation Indivior PLC, a pharmaceutical company trading on NASDAQ under ticker INDV, filed an 8-K on January 8, 2026 to disclose the issuance of a press release and updated corporate presentation ann | 2026-01-08 |
| Scheme of arrangement approved to make Indivior Pharmaceuticals parent company Indivior PLC shareholders overwhelmingly approved a restructuring deal on December 11, 2025, where the company will become a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc. In the | 2025-12-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Indivior PLC Ordinary Shares — free to start.
Google PlayApp StoreData updated 2026-09-18.